Evidence map›Paper›PMID 18469148›Full record

Trial reportAmerican journal of physiology. Heart and circulatory physiology2008

Intradermal angiotensin II administration attenuates the local cutaneous vasodilator heating response.

Julian M Stewart, Indu Taneja, Neeraj Raghunath, Debbie Clarke, Marvin S Medow

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in American journal of physiology. Heart and circulatory physiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 29 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Ascorbate improves circulation in postural tachycardia syndrome.American journal of physiology. Heart and circulatory physiology · 2011
    Article
  12. Article
  13. Article
  14. Local thermal control of the human cutaneous circulation.Journal of applied physiology (Bethesda, Md. : 1985) · 2010
    Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Julian M StewartNew York Medical College, Hawthorne, NY 10532, USA. julian_stewart@nymc.edu
Indu Taneja
Neeraj Raghunath
Debbie Clarke
Marvin S Medow
New York Medical College · US

Funding

Local Vasoconstriction in Postural Tachycardia SyndromeR01HL074873 · NHLBI · NEW YORK MEDICAL COLLEGE · PI STEWART, JULIAN M · 2004 to 2013
$3.4M
Vascular Dysfunction in CFSR01HL087803 · NHLBI · NEW YORK MEDICAL COLLEGE · PI STEWART, JULIAN M · 2008 to 2011
$1.6M
Detecting Endothelial Dysfunction in Renal FailureR21DK071647 · NIDDK · NEW YORK MEDICAL COLLEGE · PI STEWART, JULIAN M · 2006 to 2007
$426k
NHLBI NIH HHS 1-R01-HL-074873NHLBI NIH HHS R01 HL074873NHLBI NIH HHS R01 HL087803NIDDK NIH HHS 1R-21-DK-071647
6 · The paper itself

Abstract

The vasodilation response to local cutaneous heating is nitric oxide (NO) dependent and blunted in postural tachycardia but reversed by angiotensin II (ANG II) type 1 receptor (AT(1)R) blockade. We tested the hypothesis that a localized infusion of ANG II attenuates vasodilation to local heating in healthy volunteers. We heated the skin of a calf to 42 degrees C and measured local blood flow to assess the percentage of maximum cutaneous vascular conductance (%CVC(max)) in eight healthy volunteers aged 19.5-25.5 years. Initially, two experiments were performed; in one, Ringer solution was perfused in three catheters, the response to heating was measured, 2 microg/l losartan, 10 mM nitro-l-arginine (NLA), or NLA + losartan was added to perfusate, and the heat response was remeasured; in another, 10 microM ANG II was given, the heat response was measured, losartan, NLA, or NLA + losartan was added to ANG II, and the heat response was reassessed. The heat response decreased with ANG II, particularly the plateau phase (47 +/- 5 vs. 84 +/- 3 %CVC(max)). Losartan increased baseline conductance in both experiments (from 8 +/- 1 to 20 +/- 2 and 12 +/- 1 to 24 +/- 3). Losartan increased the ANG II response (83 +/- 4 vs. 91 +/- 6 in Ringer). NLA decreased both angiotensin and Ringer responses (31 +/- 4 vs. 43 +/- 3). NLA + losartan blunted the Ringer response (48 +/- 2), but the ANG II response (74 +/- 5) increased. In a second set of experiments, we used dose responses to ANG II (0.1 nM to 10 microM) with and without NLA + losartan to confirm graded responses. Sodium ascorbate (10 mM) restored the ANG II-blunted heating plateau. NO synthase and AT(1)R inhibition cause an NO-independent angiotensin-mediated vasodilation with local heating. ANG II mediates the AT(1)R blunting of local heating, which is not exclusively NO dependent, and is improved by antioxidant supplementation.

Indexed as

Hot TemperatureSkin TemperatureAdministration, CutaneousAdultAngiotensin IIAngiotensin II Type 1 Receptor BlockersAngiotensin II Type 2 Receptor BlockersAntioxidantsAscorbic AcidDose-Response Relationship, DrugEnzyme InhibitorsFemaleHumansImidazolesInfusions, ParenteralLosartanAngiotensin IIAngiotensin II Type 1 Receptor BlockersAngiotensin II Type 2 Receptor BlockersAntioxidantsAscorbic AcidEnzyme InhibitorsImidazolesLosartanNitric OxideNitric Oxide SynthaseNitroargininePD 123319PyridinesReceptor, Angiotensin, Type 2Vasoconstrictor Agents

Identifiers

PMID18469148
PMCPMC2494761
OpenAlexW2150201963

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.